You are here

JPMHC 2022

JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches

JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches

Fierce Pharma

sickle cell disease

Flag link:

JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker

JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker

Fierce Biotech

Vertex Pharmaceuticals

Flag link:

JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says

JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says

Fierce Pharma

Flag link:

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B

Fierce Pharma

Flag link:

JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch

JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch

Fierce Pharma

Flag link:

JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor

JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor

Fierce Biotech

Ionis Pharmaceuticals

Flag link:

JPM 2022: Eli Lilly CEO mulls using Novo's double-branding trick on tirzepatide—one obesity, one diabetes

JPM 2022: Eli Lilly CEO mulls using Novo's double-branding trick on tirzepatide—one obesity, one diabetes

Fierce Pharma

Flag link:

Pfizer to Increase Manufacturing of Paxlovid COVID-19 Treatment and Have Omicron-Specific Vaccine Ready by March

Pfizer to Increase Manufacturing of Paxlovid COVID-19 Treatment and Have Omicron-Specific Vaccine Ready by March

Xtalks

Flag link:

Health tech M&A is heating up

Health tech M&A is heating up

Stat

Flag link:

JPM 2022: Sanofi has designs on creating Big Pharma's 'strongest' immunology franchise, CFO says

JPM 2022: Sanofi has designs on creating Big Pharma's 'strongest' immunology franchise, CFO says

Fierce Pharma

Flag link:

JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage touts double-duty anxiety drug

JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage touts double-duty anxiety drug

Fierce Biotech

ThermoFisher Scientific

Flag link:

Sarepta DMD Treatment Improves Motor Skills in Study Presented at JPM

Sarepta DMD Treatment Improves Motor Skills in Study Presented at JPM

BioSpace

Sarepta Therapeutics

delandistrogene moxeparvovec

Duchenne Muscular Dystrophy

Flag link:

JPM22, Day 2: Sanofi's dealmaking priorities, bluebird's gene therapy goals and more

JPM22, Day 2: Sanofi's dealmaking priorities, bluebird's gene therapy goals and more

Fierce Pharma

Flag link:

JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first

JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first

Fierce Pharma

Flag link:

JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies

JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies

BioPharma Dive

Flag link:

JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff

JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff

Fierce Pharma

Bristol Myers Squibb

Flag link:

JPM 2022: Vertex's Trikafta holds the line as company lays groundwork for gene editing launch

JPM 2022: Vertex's Trikafta holds the line as company lays groundwork for gene editing launch

Fierce Pharma

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B+

JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B+

Fierce Pharma

consumer health

Flag link:

#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more

#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more

Fierce Pharma

Bristol Myers Squibb

Moderna Therapeutics

Flag link:

A late Christmas present for Allogene

A late Christmas present for Allogene

EP Vantage

Flag link:

Pages